Editorial Commentary
Will INSPIRE crown iruplinalkib as a new standard choice in first-line advanced ALK-positive non-small cell lung cancer?
Translational Lung Cancer Research
2025;
14
(3)
:653-656
.
(31 March 2025)
Optimizing long-term treatment with ALK inhibitors: balancing efficacy and safety
Translational Lung Cancer Research
2025;
14
(3)
:657-661
.
(31 March 2025)
Original Article
ANKRD11 as a potential biomarker for brain metastasis from lung adenocarcinoma via cerebrospinal fluid liquid biopsy
Translational Lung Cancer Research
2025;
14
(3)
:662-676
.
(31 March 2025)
Persistent and novel changes in plasma microRNA profiles in patients with non-small cell lung cancer following tumour resection
Translational Lung Cancer Research
2025;
14
(3)
:677-706
.
(31 March 2025)
Amivantamab as a salvage therapy post-EGFR-tyrosine kinase inhibitor failure in patients with mutated EGFR non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(3)
:707-717
.
(31 March 2025)
Circulating lung cancer exosomes damage the niche of intestinal stem cells
Translational Lung Cancer Research
2025;
14
(3)
:718-735
.
(31 March 2025)
Predicting survival in small cell lung cancer patients undergoing various treatments: a machine learning approach
Translational Lung Cancer Research
2025;
14
(3)
:736-748
.
(31 March 2025)
Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in second-line immunotherapy for patients with non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(3)
:749-760
.
(31 March 2025)
Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(3)
:761-774
.
(31 March 2025)
A better option for localization of multiple pulmonary nodules in the ipsilateral lung: electromagnetic navigation bronchoscopy-guided preoperative localization
Translational Lung Cancer Research
2025;
14
(3)
:775-784
.
(31 March 2025)
Short-term peri- and intra-tumoral CT radiomics to predict immunotherapy response in advanced non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(3)
:785-797
.
(31 March 2025)
Diagnostic utility of bronchoscopy for newly emerging peripheral pulmonary lesions after pulmonary resection
Translational Lung Cancer Research
2025;
14
(3)
:798-809
.
(31 March 2025)
Closer proximity of pre-treatment CD4+ T cells to CD8+ T cells favor response to neoadjuvant immunotherapy in patients with PD-L1 low-expressing non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(3)
:810-823
.
(31 March 2025)
Single cell RNA-seq and bulk RNA-seq analysis identifies MUC1 as a key gene for lung adenocarcinoma to neuroendocrine transformation
Translational Lung Cancer Research
2025;
14
(3)
:824-841
.
(31 March 2025)
Nomogram based on computed tomography radiomics features and clinicopathological factors to predict the prognosis of patients with non-small cell lung cancer receiving immune checkpoint inhibitor rechallenge
Translational Lung Cancer Research
2025;
14
(3)
:842-856
.
(31 March 2025)
Integrated multiomics machine learning and mediated Mendelian randomization investigate the molecular subtypes and prognosis lung squamous cell carcinoma
Translational Lung Cancer Research
2025;
14
(3)
:857-877
.
(31 March 2025)
Targeting of arachidonic acid-modulated autophagy to enhance the sensitivity of ROS1+ or ALK+ non-small cell lung cancer to crizotinib therapy
Translational Lung Cancer Research
2025;
14
(3)
:878-896
.
(31 March 2025)
Enhancing the precision of auxiliary diagnosis for lung cancer through use of SHOX2 and RASSF1A methylation status in lung biopsy and lymph node biopsy specimens
Translational Lung Cancer Research
2025;
14
(3)
:897-911
.
(31 March 2025)
Analysis of baseline interstitial lung abnormality on the risk of checkpoint inhibitor-related pneumonitis and survival in advanced non-small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors
Translational Lung Cancer Research
2025;
14
(3)
:912-930
.
(31 March 2025)
Palliative surgery is effective in patients with EGFR-mutant lung adenocarcinoma with pleural metastasis
Translational Lung Cancer Research
2025;
14
(3)
:931-939
.
(31 March 2025)
Identification and validation of crotonylation-related diagnostic markers for lung adenocarcinoma via weighted correlation network analysis and machine learning
Translational Lung Cancer Research
2025;
14
(3)
:940-962
.
(31 March 2025)
Neoadjuvant immunochemotherapy demonstrated improved efficacy and comparable safety to neoadjuvant chemotherapy for limited-stage small-cell lung cancer: a cohort study
Translational Lung Cancer Research
2025;
14
(3)
:963-974
.
(31 March 2025)
Review Article
Recent advancements in lung cancer research: a narrative review
Translational Lung Cancer Research
2025;
14
(3)
:975-990
.
(31 March 2025)
Multidisciplinary management of N2 stage III non-small cell lung cancer: opportunities and challenges for radiation oncology
Translational Lung Cancer Research
2025;
14
(3)
:991-1006
.
(31 March 2025)
Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review
Translational Lung Cancer Research
2025;
14
(3)
:1007-1020
.
(31 March 2025)
Case Report
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report
Translational Lung Cancer Research
2025;
14
(3)
:1021-1031
.
(31 March 2025)
Pathological complete response and long-term survival by pembrolizumab based immunochemotherapy in epidermal growth factor receptor mutated non-small cell lung cancer post-tyrosine kinase inhibitor failure: a case report and tumor microenvironment analysis
Translational Lung Cancer Research
2025;
14
(3)
:1032-1041
.
(31 March 2025)
